"We are enthusiastic about our investment in Accuri," said Bahaa Fam, Venture Partner, Fidelity Biosciences. "By making flow cytometry technology more affordable, accessible and usable, Accuri's high performance systems have the potential to accelerate and broaden the scope of biomedical research. We welcome this opportunity to help the company progress to the next level."
"Flow cytometry is an essential tool in biomedical research, and Accuri's outstanding team has responded to the need for accessible, affordable easy-to- use systems by completely re-inventing the flow cytometer from the ground up," said Harry Wilcox, Partner at Flagship Ventures. "The Accuri Flow Cytometer System is already gaining traction among researchers, and we are very optimistic about the future potential of this promising company."
"As Accuri continues to commercialize its revolutionary technology, we are very pleased to welcome Fidelity and Flagship representatives as new investors and as Board members," said Pete Shagory, Accuri Chairman and a Partner at Baird Venture Partners. "Their expertise in the research tools space will be especially valuable as Accuri expands its efforts to effectively grow the business."
About Accuri Cytometers
Accuri Cytometers, Inc. is an Ann Arbor-based life sciences company
developing and marketing revolutionary high performance cell analysis
systems designed to bring the power of flow cytometry into the labs of life
sciences researchers everywhere. Reflecting the input of hundreds of
researchers, the Accuri C6 Flow Cytometer(R) is a full featured bench-top
cell and bead analysis system that provides similar capabilities to those
|SOURCE Accuri Cytometers Inc.|
Copyright©2008 PR Newswire.
All rights reserved